169 related articles for article (PubMed ID: 31414747)
21. [Cryptates applied in tumor marker assays (CEA, AFP, CA 15.3, CA19.9): evaluation of Kryptor (Cis-Bio) analyser].
Gherardi C; Roumier AS; Dubucquoi S; Dessaint JP
Ann Biol Clin (Paris); 1998; 56(1):92-5. PubMed ID: 9754229
[No Abstract] [Full Text] [Related]
22. Interlaboratory surveys of the determination of tumour markers scatter and repeatability of the results.
Kruse R; Geilenkeuser WJ; Röhle G
Eur J Clin Chem Clin Biochem; 1993 Mar; 31(3):139-46. PubMed ID: 7683915
[TBL] [Abstract][Full Text] [Related]
23. [Determination of 2 tumor markers (alpha-fetoprotein and carcinoembryonic antigen) in the serum by a new immunonephelometric technique].
Gray H; Sauger F; Maitrot B
Ann Biol Clin (Paris); 1997; 55(6):597-600. PubMed ID: 9499921
[No Abstract] [Full Text] [Related]
24. SR1 assays of alpha-fetoprotein, carcinoembryonic antigen, and prostate-specific antigen compared with corresponding established commercial assays.
Jolley NL; Bacarese-Hamilton T
Clin Chem; 1994 Jun; 40(6):895-9. PubMed ID: 7522136
[TBL] [Abstract][Full Text] [Related]
25. Quantification of Cancer Biomarkers in Serum Using Scattering-Based Quantitative Single Particle Intensity Measurement with a Dark-Field Microscope.
Poon CY; Wei L; Xu Y; Chen B; Xiao L; Li HW
Anal Chem; 2016 Sep; 88(17):8849-56. PubMed ID: 27514775
[TBL] [Abstract][Full Text] [Related]
26. Reference intervals for serum alpha-fetoprotein and carcinoembryonic antigen in Chinese Han ethnic males from the Fangchenggang Area Male Health and Examination Survey.
Qin X; Lin L; Mo Z; Lv H; Gao Y; Tan A; Yang X; Li S; Zhao J
Int J Biol Markers; 2011; 26(1):65-71. PubMed ID: 21337313
[TBL] [Abstract][Full Text] [Related]
27. Elecsys CEA, PSA and AFP. Clinical results of a multicentre evaluation.
Uhl W; Chan DW; Jones K; Kelley C; Assmann G; von Eckardstein A; Sägers A; Yvert JP; Schneider AM; Torralba A; Fuentes-Arderiu X; Gonzalez de la Presa B; Vives M; Greiling H; Eberle A; Niederau CM; Cremer P; Reiter W; Vogeser M; Neumeier D; Luppa P; Huber U
Wien Klin Wochenschr; 1998; 110 Suppl 3():51-61. PubMed ID: 9677672
[TBL] [Abstract][Full Text] [Related]
28. Influence of cardiopulmonary resuscitation on levels of tumour markers.
Berent R; Auer J; Porodko M; Lamm G; Weber T; Wimmer E; Seier J; Aspöck G; Eber B
Eur J Cancer Care (Engl); 2006 Jul; 15(3):252-6. PubMed ID: 16882121
[TBL] [Abstract][Full Text] [Related]
29. Clinical Performance of CEA, CA19-9, CA15-3, CA125 and AFP in Gastrointestinal Cancer Using LOCI™-based Assays.
Dolscheid-Pommerich RC; Manekeller S; Walgenbach-Brünagel G; Kalff JC; Hartmann G; Wagner BS; Holdenrieder S
Anticancer Res; 2017 Jan; 37(1):353-359. PubMed ID: 28011514
[TBL] [Abstract][Full Text] [Related]
30. Chitosan coated copper and cadmium hexacyanocobaltate nanocubes as immunosensing probes for the construction of multiple analytes platform.
Wang Z; Chen X; Ma Z
Biosens Bioelectron; 2014 Nov; 61():562-8. PubMed ID: 24953843
[TBL] [Abstract][Full Text] [Related]
31. Au-ionic liquid functionalized reduced graphene oxide immunosensing platform for simultaneous electrochemical detection of multiple analytes.
Liu N; Ma Z
Biosens Bioelectron; 2014 Jan; 51():184-90. PubMed ID: 23962704
[TBL] [Abstract][Full Text] [Related]
32. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
33. Trimetallic Pd@Au@Pt nanocomposites platform on -COOH terminated reduced graphene oxide for highly sensitive CEA and PSA biomarkers detection.
Barman SC; Hossain MF; Yoon H; Park JY
Biosens Bioelectron; 2018 Feb; 100():16-22. PubMed ID: 28850823
[TBL] [Abstract][Full Text] [Related]
34. Immunosensing procedures for carcinoembryonic antigen using graphene and nanocomposites.
Luong JHT; Vashist SK
Biosens Bioelectron; 2017 Mar; 89(Pt 1):293-304. PubMed ID: 26620098
[TBL] [Abstract][Full Text] [Related]
35. Multiplexed detection of tumor markers with multicolor quantum dots based on fluorescence polarization immunoassay.
Tian J; Zhou L; Zhao Y; Wang Y; Peng Y; Zhao S
Talanta; 2012 Apr; 92():72-7. PubMed ID: 22385810
[TBL] [Abstract][Full Text] [Related]
36. Ultrasensitive non enzymatic multiple immunosensor for tumor markers detection by coupling DNA hybridization chain reaction with intercalated molecules.
Guo J; Wang J; Zhang J; Zhang W; Zhang Y
Biosens Bioelectron; 2017 Apr; 90():159-165. PubMed ID: 27888684
[TBL] [Abstract][Full Text] [Related]
37. Triple tumor markers assay based on carbon-gold nanocomposite.
Xu T; Liu N; Yuan J; Ma Z
Biosens Bioelectron; 2015 Aug; 70():161-6. PubMed ID: 25814405
[TBL] [Abstract][Full Text] [Related]
38. A label-free immunosensor based on modified mesoporous silica for simultaneous determination of tumor markers.
Lin J; Wei Z; Mao C
Biosens Bioelectron; 2011 Nov; 29(1):40-5. PubMed ID: 21871790
[TBL] [Abstract][Full Text] [Related]
39. A vertical flow microarray chip based on SERS nanotags for rapid and ultrasensitive quantification of α-fetoprotein and carcinoembryonic antigen.
Zhang D; Huang L; Liu B; Ge Q; Dong J; Zhao X
Mikrochim Acta; 2019 Oct; 186(11):699. PubMed ID: 31617008
[TBL] [Abstract][Full Text] [Related]
40. Indicators of inappropriate tumour marker use through the mining of electronic health records.
Gion M; Cardinali G; Trevisiol C; Zappa M; Rainato G; Fabricio ASC
J Eval Clin Pract; 2017 Aug; 23(4):895-902. PubMed ID: 28503788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
